This medical app provides a fast and clear way to evaluate and manage infant jaundice. It offers interpretations of bilirubin risk zones, plotting on nomograms, and management recommendations based on AAP guidelines. It also supports Apple Watch for quick access to information.
2.2
February 23, 2018
This update from Apple will improve the functionality of this app. No new features are included. • Supports iPhone X and iOS 11! • Updated graphics and refreshed icons • Change bilirubin units directly on Apple Watch app • Haptic on bilirubin units change on iPhone • Performance improvements and bug fixes
MoreBili QuikCalc is a medical application designed to help healthcare professionals quickly evaluate and manage infants with jaundice. It provides interpretations of bilirubin risk zones and recommendations for assessment and follow-up based on the latest AAP guidelines.
Key features include a fast bilirubin calculator, plotting of bilirubin levels on risk nomograms, viewing bilirubin thresholds for different gestational ages, and support for Apple Watch for on-the-go access to risk zone interpretations.
Yes, Bili QuikCalc is based on the latest recommendations from the AAP Subcommittee on Hyperbilirubinemia, ensuring that users have access to up-to-date information for managing newborn jaundice.
Yes, Bili QuikCalc is the first and only bilirubin calculator to support Apple Watch. This allows users to check and plot bilirubin risk directly on their wrist for quick evaluations.
Bili QuikCalc is a paid application, available for $0.99. This one-time purchase grants access to all its features for evaluating and managing infant jaundice.
Bili QuikCalc is supported on a range of Apple devices, including iPhone, iPad, iPod, and Apple Watch. This broad compatibility ensures accessibility for various healthcare settings.
The latest version, 2.2, was released on February 23, 2018. While updates have not been frequent recently, users can find details about new features and functions in the app's Help file.
Bili QuikCalc has an age rating of 12+. This indicates that the content is generally suitable for individuals aged 12 and older, though its primary audience is medical professionals.
